Influenza A Infections - Pipeline Review, H2 2014

Date: September 30, 2014
Pages: 141
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ID6E48B0185EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Influenza A Infections - Pipeline Review, H2 2014’, provides an overview of the Influenza A Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Influenza A Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Influenza A Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Influenza A Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Influenza A Infections Overview
Therapeutics Development
Pipeline Products for Influenza A Infections - Overview
Pipeline Products for Influenza A Infections - Comparative Analysis
Influenza A Infections - Therapeutics under Development by Companies
Influenza A Infections - Therapeutics under Investigation by Universities/Institutes
Influenza A Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Influenza A Infections - Products under Development by Companies
Influenza A Infections - Products under Investigation by Universities/Institutes
Influenza A Infections - Companies Involved in Therapeutics Development
Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Autoimmune Technologies, LLC
GlaxoSmithKline plc
Genentech, Inc.
Inovio Pharmaceuticals, Inc.
MedImmune, LLC
Crucell N.V.
Hemispherx Biopharma, Inc.
NanoViricides, Inc.
SIGA Technologies, Inc. (Inactive)
Vironova AB
CureVac GmbH
Chimerix, Inc.
Theraclone Sciences, Inc.
Immune Targeting Systems (ITS) Ltd.
Sinovac Biotech Ltd.
Microbiotix, Inc.
iBio, Inc.
Alios BioPharma, Inc.
Vivaldi Biosciences Inc.
Visterra, Inc.
ContraFect Corporation
Cure Lab, Inc.
Humabs BioMed SA
Microgen Scientific Industrial Company for Immunobiological Medicines
Influenza A Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
FP-01 - Drug Profile
CR-8020 - Drug Profile
TCN-032 - Drug Profile
influenza vaccine (H5N2) - Drug Profile
RG-7745 - Drug Profile
diridavumab - Drug Profile
MEDI-550 - Drug Profile
influenza A vaccine (H7N7) - Drug Profile
VIS-410 - Drug Profile
Live Attenuated Vaccine for H5N2 Influenza - Drug Profile
GSK-3206641A - Drug Profile
GSK-3206640A - Drug Profile
Influenza A Vaccine [H7N9] - Drug Profile
GSK-3277510A - Drug Profile
GSK-3277509A - Drug Profile
Influenza Vaccine [H7N9] - Drug Profile
interferon alfa-n3 - Drug Profile
NVINF-2 - Drug Profile
Pandemic Influenza Vaccine (H1N1) - Drug Profile
Flufirvitide-3 - Drug Profile
NVINF-1 - Drug Profile
Nucleozin - Drug Profile
Small Molecule for Influenza A - Drug Profile
ET-001 - Drug Profile
CR-8043 - Drug Profile
FI-6 - Drug Profile
DNA Vaccine for H7N9 Universal Influenza - Drug Profile
Peptides for Influenza Infections - Drug Profile
Gamma-Flu - Drug Profile
Peptide to Agonize PAR-2 for Influenza A Infections - Drug Profile
VH-244 - Drug Profile
CF-401 - Drug Profile
CF-402 - Drug Profile
Panavimab A - Drug Profile
CLVax-1.0 - Drug Profile
Z-3G1 - Drug Profile
Small Molecules for Influenza A Infections - Drug Profile
Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A Virus Infections - Drug Profile
Small Molecule To Inhibit Hemagglutinin For Influenza A - Drug Profile
Small Molecules to Block Influenza M2 Proton Channel for Influenza A Infections - Drug Profile
AL-18 - Drug Profile
influenza vaccine (H7N9) - Drug Profile
MBX-2329 - Drug Profile
MBX-2546 - Drug Profile
Recombinant Peptides for HIV-1 Infection and Influenza A Infections - Drug Profile
Small Molecule for Influenza Virus - Drug Profile
Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile
VX-353 - Drug Profile
Small Molecules to Block M2 Proton Channel for Influenza A Infections - Drug Profile
Influenza A Infections - Recent Pipeline Updates
Influenza A Infections - Dormant Projects
Influenza A Infections - Discontinued Products
Influenza A Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES


Number of Products under Development for Influenza A Infections, H2 2014
Number of Products under Development for Influenza A Infections - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Development by Companies, H2 2014 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Development by Companies, H2 2014 (Contd..1)
Products under Development by Companies, H2 2014 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2014
Influenza A Infections - Pipeline by Johnson & Johnson, H2 2014
Influenza A Infections - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014
Influenza A Infections - Pipeline by Autoimmune Technologies, LLC, H2 2014
Influenza A Infections - Pipeline by GlaxoSmithKline plc, H2 2014
Influenza A Infections - Pipeline by Genentech, Inc., H2 2014
Influenza A Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014
Influenza A Infections - Pipeline by MedImmune, LLC, H2 2014
Influenza A Infections - Pipeline by Crucell N.V., H2 2014
Influenza A Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2014
Influenza A Infections - Pipeline by NanoViricides, Inc., H2 2014
Influenza A Infections - Pipeline by SIGA Technologies, Inc. (Inactive), H2 2014
Influenza A Infections - Pipeline by Vironova AB, H2 2014
Influenza A Infections - Pipeline by CureVac GmbH, H2 2014
Influenza A Infections - Pipeline by Chimerix, Inc., H2 2014
Influenza A Infections - Pipeline by Theraclone Sciences, Inc., H2 2014
Influenza A Infections - Pipeline by Immune Targeting Systems (ITS) Ltd., H2 2014
Influenza A Infections - Pipeline by Sinovac Biotech Ltd., H2 2014
Influenza A Infections - Pipeline by Microbiotix, Inc., H2 2014
Influenza A Infections - Pipeline by iBio, Inc., H2 2014
Influenza A Infections - Pipeline by Alios BioPharma, Inc., H2 2014
Influenza A Infections - Pipeline by Vivaldi Biosciences Inc., H2 2014
Influenza A Infections - Pipeline by Visterra, Inc., H2 2014
Influenza A Infections - Pipeline by ContraFect Corporation, H2 2014
Influenza A Infections - Pipeline by Cure Lab, Inc., H2 2014
Influenza A Infections - Pipeline by Humabs BioMed SA, H2 2014
Influenza A Infections - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Influenza A Infections Therapeutics - Recent Pipeline Updates, H2 2014
Influenza A Infections - Dormant Projects, H2 2014
Influenza A Infections - Discontinued Products, H2 2014

LIST OF FIGURES


Number of Products under Development for Influenza A Infections, H2 2014
Number of Products under Development for Influenza A Infections - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014
Skip to top


Influenza B Infections - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 83 pages
Herpes Simplex Infections - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 185 pages

Ask Your Question

Influenza A Infections - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: